331 related articles for article (PubMed ID: 18450470)
1. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.
Palmer G; Lipsky BP; Smithgall MD; Meininger D; Siu S; Talabot-Ayer D; Gabay C; Smith DE
Cytokine; 2008 Jun; 42(3):358-64. PubMed ID: 18450470
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity.
Hong K; Lee Y; Lee S; Hong S; Bae S; Hong J; Choi J; Jhun H; Kwak A; Kim E; Jo S; Kang T; Cho YS; Kim YG; Kim S
Immunol Res; 2013 May; 56(1):122-30. PubMed ID: 23435764
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.
Moulin D; Donzé O; Talabot-Ayer D; Mézin F; Palmer G; Gabay C
Cytokine; 2007 Dec; 40(3):216-25. PubMed ID: 18023358
[TBL] [Abstract][Full Text] [Related]
4. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.
Chackerian AA; Oldham ER; Murphy EE; Schmitz J; Pflanz S; Kastelein RA
J Immunol; 2007 Aug; 179(4):2551-5. PubMed ID: 17675517
[TBL] [Abstract][Full Text] [Related]
5. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells.
Drube S; Heink S; Walter S; Löhn T; Grusser M; Gerbaulet A; Berod L; Schons J; Dudeck A; Freitag J; Grotha S; Reich D; Rudeschko O; Norgauer J; Hartmann K; Roers A; Kamradt T
Blood; 2010 May; 115(19):3899-906. PubMed ID: 20200353
[TBL] [Abstract][Full Text] [Related]
6. Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice.
Zhao J; Zhang H; Liu SB; Han P; Hu S; Li Q; Wang ZF; Mao-Ying QL; Chen HM; Jiang JW; Wu GC; Mi WL; Wang YQ
Neuroscience; 2013 Dec; 253():172-82. PubMed ID: 23988433
[TBL] [Abstract][Full Text] [Related]
7. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.
Schmitz J; Owyang A; Oldham E; Song Y; Murphy E; McClanahan TK; Zurawski G; Moshrefi M; Qin J; Li X; Gorman DM; Bazan JF; Kastelein RA
Immunity; 2005 Nov; 23(5):479-90. PubMed ID: 16286016
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the interaction of IL-33 with its receptors.
Liu X; Hammel M; He Y; Tainer JA; Jeng US; Zhang L; Wang S; Wang X
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14918-23. PubMed ID: 23980170
[TBL] [Abstract][Full Text] [Related]
9. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.
Hayakawa H; Hayakawa M; Kume A; Tominaga S
J Biol Chem; 2007 Sep; 282(36):26369-80. PubMed ID: 17623648
[TBL] [Abstract][Full Text] [Related]
10. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1.
Kumar S; Minnich MD; Young PR
J Biol Chem; 1995 Nov; 270(46):27905-13. PubMed ID: 7499265
[TBL] [Abstract][Full Text] [Related]
11. Special aspects of interleukin-33 and the IL-33 receptor complex.
Martin MU
Semin Immunol; 2013 Dec; 25(6):449-57. PubMed ID: 24230466
[TBL] [Abstract][Full Text] [Related]
12. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice.
Ouziel R; Gustot T; Moreno C; Arvanitakis M; Degré D; Trépo E; Quertinmont E; Vercruysse V; Demetter P; Le Moine O; McKenzie AN; Delhaye M; Devière J; Lemmers A
Am J Pathol; 2012 Jun; 180(6):2330-9. PubMed ID: 22542450
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 requires CMRF35-like molecule-1 expression for induction of myeloid cell activation.
Shik D; Moshkovits I; Karo-Atar D; Reichman H; Munitz A
Allergy; 2014 Jun; 69(6):719-29. PubMed ID: 24735452
[TBL] [Abstract][Full Text] [Related]
14. IL-33/ST2 axis promotes mast cell survival via BCLXL.
Wang JX; Kaieda S; Ameri S; Fishgal N; Dwyer D; Dellinger A; Kepley CL; Gurish MF; Nigrovic PA
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10281-6. PubMed ID: 24982172
[TBL] [Abstract][Full Text] [Related]
15. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
Sanada S; Hakuno D; Higgins LJ; Schreiter ER; McKenzie AN; Lee RT
J Clin Invest; 2007 Jun; 117(6):1538-49. PubMed ID: 17492053
[TBL] [Abstract][Full Text] [Related]
16. Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo.
Saccani S; Polentarutti N; Penton-Rol G; Sims JE; Mantovani A
Cytokine; 1998 Oct; 10(10):773-80. PubMed ID: 9811530
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of ST2 (IL-1R4) specific for IL-33 activity; no suppression by IL-1Ra though a common chain IL-1R3 (IL-1RAcP) shared with IL-1.
Jo S; Kim E; Kwak A; Lee J; Hong J; Lee J; Youn S; Bae S; Kim B; Ryoo S; Kang TB; Her E; Choi DK; Kim YS; Lee Y; Jhun H; Kim S
Cytokine; 2016 Jul; 83():33-40. PubMed ID: 27031441
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells.
Schmieder A; Multhoff G; Radons J
Cytokine; 2012 Nov; 60(2):514-21. PubMed ID: 22819319
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-33 mediates formalin-induced inflammatory pain in mice.
Han P; Zhao J; Liu SB; Yang CJ; Wang YQ; Wu GC; Xu DM; Mi WL
Neuroscience; 2013 Jun; 241():59-66. PubMed ID: 23523996
[TBL] [Abstract][Full Text] [Related]
20. Clock-dependent temporal regulation of IL-33/ST2-mediated mast cell response.
Kawauchi T; Ishimaru K; Nakamura Y; Nakano N; Hara M; Ogawa H; Okumura K; Shibata S; Nakao A
Allergol Int; 2017 Jul; 66(3):472-478. PubMed ID: 28259547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
